Welcome to the 2021 LUPUS CORA Meeting Program Scheduling
The meeting will officially run on Central European Summer Time (CEST), GMT +2
To convert the meeting times to your local time Click Here
CORA Topics || ASL15 IL17, TH17 AND CYTOKINES IN AUTOIMMUNITY, CORA Topics || ASL28 RHEUMATOID ARTHRITIS, No Topic Needed
- Fabiola Atzeni (Italy)
Introduction and Polling by Chairperson
- Fabiola Atzeni (Italy)
Can Pain and Fatigue in RA patient. Are small molecules better than biologics? YES: small molecules are better
- Piercarlo Sarzi-Puttini (Italy)
Can Pain and Fatigue in RA patient. Are small molecules better than biologics? NO: biologics better
- Daniel Aletaha (Austria)
Live rebuttal
- Piercarlo Sarzi-Puttini (Italy)
Live rebuttal
- Daniel Aletaha (Austria)
Panel discussion – Live
COMPARISON OF RHEUMATOID ARTHRITIS PATIENTS RECENTLY SWITCHED TO JAK INHIBITOR THERAPY IN THE US AND EU5: COMORBIDITY AND SWITCH PATTERN ANALYSIS FROM PATIENT CHART AUDIT
- Maxine Yarnall (United States of America)
Abstract
Background and Aims
As use of Janus Kinase inhibitor (JAKi) therapies in rheumatoid arthritis (RA) have increased, so has awareness of cardiovascular (CV) and malignancy safety concerns associated with the class. This study’s goal is to compare gender, comorbidities, and JAKi use in RA patients switched to JAKi therapies in the US and EU5.
Methods
In July-September 2020, US (n=200) and EU5 (n=310) rheumatologists contributed patient chart data for biologic/JAK treated RA patients (US (n=1,000); EU5 (n=1,288)). Data has been collected annually in the US since 2016 and EU5, 2017.
Results
US females switched to a JAKi therapy were statistically more likely to have a high CV risk and obesity compared to EU5 females. EU5 males were statistically more likely to have malignancy risk and a history of smoking than US males. Additionally, statistical differences were found between the genders within a region. Tofacitinib use is higher than baricitinib in the US, while the opposite in the EU5. JAK cycling has increased in both regions year over year.
| Cardiovascular Risk | Malignancy Risk | Cancer | DVT/PE | High BP | Hyperlipidemia | MI | Obesity | Smoker | None | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| EU5 JAK patients | Male (95) | 25.26% | 18.95% | 2.11% | 2.11% | 38.95% | 28.42% | 7.37% | 13.68% | 25.26% | 21.05% |
| Female (199) | 9.05% | 11.06% | 1.01% | 0.00% | 23.62% | 10.55% | 0.50% | 9.55% | 9.05% | 35.18% | |
| US JAK patients | Male (110) | 25.45% | 8.18% | 1.82% | 1.82% | 41.82% | 30.00% | 4.55% | 20.00% | 6.36% | 26.36% |
| Female (196) | 15.82% | 14.80% | 1.53% | 0.00% | 28.06% | 15.82% | 1.02% | 21.94% | 7.14% | 26.53% |
Conclusions
Different considerations between genders and regions should be given when switching RA patients to JAKi therapy in the US and EU5.
Live Q&A
A NEW APPROACH TO INTERLEUKINE 8 IN RHEUMATOID ARTHRITIS - THE ASSOCIATION WITH ACPA AND DISEASE ACTIVITY.
- Aleksandra Starzyk (Poland)
Abstract
Background and Aims
Proinflammatory cytokines play critical role in the pathophisology of rheumatoid arthritis (RA). Recent studies concerning IL-8 support its role in ACPA-mediated osteoclast activation as a mechanism of arthralgia and bone loss, but the functional involvement of this cytokine are still uninvestigated. This analysis aimed to determine the association of IL-8 cytokine levels with clinical variables in patients with RA.
Methods
63 patients with RA and 25 patients in control group were included in this study. The cytokines levels in serum were evaluated by the ProcartaPlex immunoassays kits (eBioscience, Affymetrix) on the Luminex xMAP system according to manufacturer’s instruction.
Results
IL-8 was elevated in RA patient group (p<0.0001). We found differences between control group and RA activity groups according to Disease Activity Score in 28 joints (Figure1.).
Figure 1. IL-8 concentration in RA and healthy control. Blue line connects medians.
IL-8 was also positively correlated with C-reaction protein (r=0,43), erythrocyte sedimentation rate (r=0,4), level of autoantibodies (RF: r=0,54; ACPA: r=0,51). Furthermore there was correlation between IL-8 and number of swollen (r=0.38) and painfull joints (r=0.33).
Conclusions
Circulating IL-8 is correlated with disease activity and ACPA, therefore may impact the pathogenesis and progression of RA and may be the point of further investigations.
Live Q&A
Live Session summary by Chairperson
- Fabiola Atzeni (Italy)